Cargando…
Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease
AIMS: The aim of this study was to determine if elastin content in needle core native liver biopsies was predictive of clinical outcome in patients with chronic hepatitis C virus‐related chronic liver disease. METHODS AND RESULTS: Elastin contents in liver biopsies were determined by image analysis,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033111/ https://www.ncbi.nlm.nih.gov/pubmed/29464815 http://dx.doi.org/10.1111/his.13499 |
_version_ | 1783337637733466112 |
---|---|
author | Kendall, Timothy J Dolman, Grace E Duff, Catherine M Paish, Emma C Zaitoun, Abed Irving, William Fallowfield, Jonathan A Guha, Indra N |
author_facet | Kendall, Timothy J Dolman, Grace E Duff, Catherine M Paish, Emma C Zaitoun, Abed Irving, William Fallowfield, Jonathan A Guha, Indra N |
author_sort | Kendall, Timothy J |
collection | PubMed |
description | AIMS: The aim of this study was to determine if elastin content in needle core native liver biopsies was predictive of clinical outcome in patients with chronic hepatitis C virus‐related chronic liver disease. METHODS AND RESULTS: Elastin contents in liver biopsies were determined by image analysis, technically validated in an independent centre, and correlated with outcome in patients with advanced (Ishak stage ≥5) chronic hepatitis C virus‐related chronic liver disease. Elastin was robustly quantified in an operator‐independent and laboratory‐independent manner, with very strong correlation of elastin staining measured with two methods of image classification (r (s) = 0.873, P < 0.00001). Elastin content (but not absolute scar content or Ishak stage) was predictive for future clinical outcomes. In a cohort of patients without sustained virological response, the median hepatic elastin content was 3.4%, and 17 patients (57%) progressed to a liver‐related clinical outcome; 11 of the 15 patients (73%) with a hepatic elastin content of >3.4% progressed to a clinical outcome, as compared with only six of 15 (40%) with an elastin content of <3.4%. The difference in time to outcome was significant. CONCLUSIONS: We describe a simple and reproducible method for elastin quantification in liver biopsies that provides potentially valuable prognostic information to inform clinical management. |
format | Online Article Text |
id | pubmed-6033111 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-60331112018-07-12 Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease Kendall, Timothy J Dolman, Grace E Duff, Catherine M Paish, Emma C Zaitoun, Abed Irving, William Fallowfield, Jonathan A Guha, Indra N Histopathology Original Articles AIMS: The aim of this study was to determine if elastin content in needle core native liver biopsies was predictive of clinical outcome in patients with chronic hepatitis C virus‐related chronic liver disease. METHODS AND RESULTS: Elastin contents in liver biopsies were determined by image analysis, technically validated in an independent centre, and correlated with outcome in patients with advanced (Ishak stage ≥5) chronic hepatitis C virus‐related chronic liver disease. Elastin was robustly quantified in an operator‐independent and laboratory‐independent manner, with very strong correlation of elastin staining measured with two methods of image classification (r (s) = 0.873, P < 0.00001). Elastin content (but not absolute scar content or Ishak stage) was predictive for future clinical outcomes. In a cohort of patients without sustained virological response, the median hepatic elastin content was 3.4%, and 17 patients (57%) progressed to a liver‐related clinical outcome; 11 of the 15 patients (73%) with a hepatic elastin content of >3.4% progressed to a clinical outcome, as compared with only six of 15 (40%) with an elastin content of <3.4%. The difference in time to outcome was significant. CONCLUSIONS: We describe a simple and reproducible method for elastin quantification in liver biopsies that provides potentially valuable prognostic information to inform clinical management. John Wiley and Sons Inc. 2018-04-16 2018-07 /pmc/articles/PMC6033111/ /pubmed/29464815 http://dx.doi.org/10.1111/his.13499 Text en © 2018 The Authors. Histopathology published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Kendall, Timothy J Dolman, Grace E Duff, Catherine M Paish, Emma C Zaitoun, Abed Irving, William Fallowfield, Jonathan A Guha, Indra N Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease |
title | Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease |
title_full | Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease |
title_fullStr | Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease |
title_full_unstemmed | Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease |
title_short | Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease |
title_sort | hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033111/ https://www.ncbi.nlm.nih.gov/pubmed/29464815 http://dx.doi.org/10.1111/his.13499 |
work_keys_str_mv | AT kendalltimothyj hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease AT dolmangracee hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease AT duffcatherinem hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease AT paishemmac hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease AT zaitounabed hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease AT irvingwilliam hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease AT fallowfieldjonathana hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease AT guhaindran hepaticelastincontentispredictiveofadverseoutcomeinadvancedfibroticliverdisease |